🎉 Free to use until Sep 16, 2026 — try it out for our launch!
STOCKIQAISTOCKIQAI
עברית
S&P 5007,709.96▼ 0.18%
Dow Jones53,885.1▼ 0.85%
Nasdaq26,348.35▼ 0.06%
Russell 20003,001.55▼ 0.58%
Fear Index (VIX)15.31▲ 1.06%
TA-125₪4,050.45▲ 0.45%
S&P 5007,709.96▼ 0.18%
Dow Jones53,885.1▼ 0.85%
Nasdaq26,348.35▼ 0.06%
Russell 20003,001.55▼ 0.58%
Fear Index (VIX)15.31▲ 1.06%
TA-125₪4,050.45▲ 0.45%

RCKT

Rocket Pharmaceuticals Inc. Common Stock

Health Care · ·

$3.54

▲ $0.04 (+1.1%)

Market Cap

$386.55M

Day Range

$3.49 - $3.62

52-Week Range

$2.53 - $5.45

Beta

—

Next Earnings

—

RCKT is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.

🏢 Similar Stocks in the Same Sector

AAPG

Ascentage Pharma Group International - American Depository

AARD

Aardvark Therapeutics, Inc.

ABCL

AbCellera Biologics Inc. - Common

+15.9% (1Y)

Some data (financial/growth/valuation) is currently unavailable — the daily API quota was likely exhausted. The score is computed from 6 of 7 available categories. Try again later for the full analysis.
Investor Score
53/ 100C-
🟡 Moderate

This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer

📈63C+Technical
💰41DFundamental
🚀68B-Growth
💎38FValuation
📰50C-News
🏦—Quality
⚠️48D+Risk

Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%

🔍 Cross-Check

Overall Score

🟡 Mixed

Technical Trend

🟢 Bullish

Insiders

🔴 Bearish

✅ Why is the score relatively high?

  • 🟢 Earnings per share (EPS) growth: 26.4%
  • 🟢 Current ratio: 6.38
  • 🟢 Price is above the 50-day average
  • 🟢 MACD histogram is positive — rising momentum
  • 🟢 RSI 54.7 — healthy positive momentum

⚠️ What's concerning?

  • 🔴 Estimated fair value: -$31.97 vs. price $3.54 (-1003.2%)
  • 🔴 ATR: 6.0% of price
  • 🔴 Return on equity (ROE): -80.5% (negative)
  • 🔴 Price is below the 200-day average
  • 🔴 -5.9% over the last 3 months relative to the index

🚦 Quality & Risk Checks

🔴 Daily volatility (ATR)🟢 Liquidity risk

📰 News Trend

Based on real financial news (Finnhub)
🟡 Mixed

Everyone's writing about Rocket Pharmaceuticals Inc. Common Stock. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 2 vs. 2 out of the last 10 articles.

🟢 Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial — Benzinga🟢 Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease — Business Wire🟡 Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease — Benzinga

News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer

📈 Technical Analysis

Based on the last 251 trading days, calculated from real price data. Click an indicator for details and a chart.

🟢 Most indicators support an uptrend (6 bullish · 3 bearish · 2 neutral)

Conclusions

  • 🟢Price vs. SMA 50 — Price is above the 50-day average
  • 🔴Price vs. SMA 200 — Price is below the 200-day average
  • 🟢MACD — MACD histogram is positive — rising momentum
  • 🟢RSI — RSI 54.7 — healthy positive momentum
  • 🔴Stochastic — %K 94.0 — overbought
  • 🟡ADX (trend strength) — ADX 16.1 — weak trend/choppy
  • 🟢Volume trend — Rising volume supports the price advance
  • 🔴Relative strength vs. S&P 500 — -5.9% over the last 3 months relative to the index
  • 🟢ROC (rate of change) — ROC 12 days: 2.0%
  • 🟢Parabolic SAR — Price is above the SAR point — uptrend
  • 🟡CMF (money flow) — CMF 20 days: 0.00

Wyckoff Method Analysis

A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.

Markup

The stock is in a clear uptrend with no defined trading range in the period examined.

Low confidence

Evidence Behind This Read

  • 🟢Rising price trend — A 16.7% change over the last 50 days, with no defined trading range.
  • 🔴Divergence between price and cumulative money flow (A/D Line) — Price and the cumulative Accumulation/Distribution Line are moving in opposite directions — a classic Wyckoff sign that the move isn't backed by real money, and may be less stable than it looks.

The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.

🎯 Trade Planning (M.A.E.E Framework)

Based on a mechanical trading method: market structure → value zone → ATR-based exit point. Not investment advice — a calculation tool only.

1️⃣ Market Structure

🟡 Range

The price is oscillating around the 200-day average with no clear direction — the method recommends great caution here (buying at the bottom of the range / selling at the top) or avoiding trading altogether.

2️⃣ Value Zone

🟡 Price far from value zone

The price is currently far from the 50-day average — the method recommends waiting for a "pullback" before entering, rather than chasing prices.

In a range, the method doesn't give a single directional stop point — the market currently lacks a clear direction, consider waiting for a breakout from the range.

💰 Financial Health

Profitability

Gross Margin

—

Operating Margin

—

Net Margin

—

EBITDA Margin

—

Efficiency

ROE

-80.5%

ROA

-67.5%

ROIC

—

EPS

-$2.01

Balance Sheet

Cash

$77.56M

Total Debt

—

Current Ratio

6.38

Debt/Equity

—

Conclusions

  • 🔴Return on equity (ROE) — Return on equity (ROE): -80.5% (negative)
  • 🔴Return on assets (ROA) — Return on assets (ROA): -67.5% — weak
  • 🟢Current ratio (liquidity) — Current ratio: 6.38
  • 🔴Interest coverage — Interest coverage: -122.6x

🚀 Growth

Revenue

Earnings per Share (EPS)

Net Income

Free Cash Flow (FCF)

Conclusions

  • 🟢Earnings per share (EPS) growth — Earnings per share (EPS) growth: 26.4%
  • 🟢Free cash flow growth — Free cash flow growth: 11.7%
  • 🟢Net income growth — Net income growth: 13.8%

💎 Fair Value (Valuation)

Current Price

$3.54

Estimated Fair Value (DCF)

-$31.97

Gap

-1003.2%

🔴 Appears expensive relative to estimated value

Show all model (DCF) assumptions →

Year 1 Growth Rate

10.0%

Discount Rate (WACC)

9.0%

Terminal Growth Rate

2.5%

Projection Years

5

YearGrowth RateProjected FCFPresent Value
110.0%$-209.50M$-192.20M
28.1%$-226.52M$-190.66M
36.3%$-240.68M$-185.85M
44.4%$-251.21M$-177.96M
52.5%$-257.49M$-167.35M

Base FCF (last actual year)

$-190.45M

Terminal Value

$-4.06B

Present Value of Terminal Value

$-2.64B

Enterprise Value

$-3.55B

Net Debt

$0

Equity Value

$-3.55B

*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.

Book Value per Share

$2.49

Tangible Book Value per Share (Tangible NAV)

$1.92

Conclusions

  • 🔴DCF Fair Value — Estimated fair value: -$31.97 vs. price $3.54 (-1003.2%)
  • 🟡Tangible Net Asset Value (NAV) — NAV per share: $1.92
  • 🟡P/E — P/E: -1.7

🕴️ Insider Trading

Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 5 sales out of the last 25 filings.

NameTransaction TypeDateSharesChangePrice
SOUTHWELL DAVID PGrant/Award from Employer18.6.202654,522+22,862—
SOUTHWELL DAVID PGrant/Award from Employer18.6.202664,860+64,860—
BOESS CARSTENGrant/Award from Employer18.6.202652,862+22,862—
BOESS CARSTENGrant/Award from Employer18.6.202664,860+64,860—
Malik Fady IbrahamGrant/Award from Employer18.6.202652,862+22,862—
Malik Fady IbrahamGrant/Award from Employer18.6.202664,860+64,860—
Dolsten MikaelGrant/Award from Employer18.6.202667,082+22,862—
Dolsten MikaelGrant/Award from Employer18.6.202664,860+64,860—
Fong PeterGrant/Award from Employer18.6.202676,195+22,862—
Fong PeterGrant/Award from Employer18.6.202664,860+64,860—
WONG RODERICKGrant/Award from Employer18.6.202675,499+27,832—
WONG RODERICKGrant/Award from Employer18.6.202678,960+78,960—
Militello JohnDisposition to the Company26.5.20260-24,545—
Militello JohnGrant/Award from Employer26.5.202651,509+51,509—
Militello JohnGrant/Award from Employer26.5.202615,002+15,002—
Militello JohnGrant/Award from Employer26.5.202616,061+16,061—
Militello JohnGrant/Award from Employer26.5.202624,899+24,899—
Militello JohnGrant/Award from Employer26.5.20269,091+9,091—
Shah GauravExercise of Derivative Securities21.5.20261,117,408+76,490$1.69
Shah GauravOpen Market Sale21.5.20261,061,724-55,684$3.09
Shah GauravExercise of Derivative Securities21.5.20260-76,490$1.69
Militello JohnOpen Market Sale19.5.202689,780-384$3.01
Wilson MartinOpen Market Sale19.5.2026677,977-662$3.01
Shah GauravOpen Market Sale19.5.20261,040,918-2,409$3.01
Militello JohnOpen Market Sale13.5.202690,164-855$3.61

📉 Short Interest

Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.

Monthly Trend — Open Short Interest

↓-8.7%

16,571,867 shares short as of 2026-07-15 · vs. 18,159,054 on 2026-06-30

Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.

Weekly Trend — Daily Short-Sale Activity

↓-13.6%

46.2% of trading volume this week was short selling, vs. 53.4% the prior week

Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.

📰 News & Sentiment

Sentiment based on basic keywords (not AI) — 2 positive, 6 neutral, 2 negative out of the last 10 articles.